News stories about Geron (NASDAQ:GERN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Geron earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.3372693794977 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Why Geron Corp. Is Rallying 10% Today (finance.yahoo.com)
- Is Geron Corporation Stock Still a Strong Buy? (finance.yahoo.com)
- A Close Look at Geron’s Imetelstat (finance.yahoo.com)
- Exploring Geron’s Financial Performance (finance.yahoo.com)
- Why Geron Corporation Stock Is Up Big Again Today (finance.yahoo.com)
GERN has been the subject of several research reports. Zacks Investment Research lowered Geron from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. BidaskClub raised Geron from a “strong sell” rating to a “sell” rating in a report on Thursday, January 11th. ValuEngine raised Geron from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. Piper Jaffray Companies reissued a “buy” rating and set a $7.00 price objective on shares of Geron in a report on Monday, March 19th. Finally, Stifel Nicolaus increased their price objective on Geron from $2.50 to $4.00 and gave the company a “hold” rating in a report on Sunday, March 18th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $4.50.
Geron (NASDAQ:GERN) last posted its quarterly earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.01). Geron had a negative return on equity of 25.25% and a negative net margin of 2,621.22%. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.41 million. During the same period in the previous year, the business earned ($0.05) earnings per share. Geron’s revenue was up 103.2% on a year-over-year basis. equities analysts predict that Geron will post 0.01 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Geron (GERN) Stock Price” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3294684/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-geron-gern-stock-price.html.
Geron Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.